Cover Image

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to these therapie...

Full description

Saved in:
Bibliographic Details
Main Authors: Torrisi, Sebastiano Emanuele (Author) , Kahn, Nicolas (Author) , Sarmand, Nilab (Author) , Polke, Markus (Author) , Eichinger, Monika (Author) , Heußel, Claus Peter (Author) , Kreuter, Michael (Author) , Kehler, Lars (Author)
Format: Article (Journal)
Language:English
Published: 12 November 2019
In: BMC pulmonary medicine
Year: 2019, Volume: 19
ISSN:1471-2466
DOI:10.1186/s12890-019-0937-0
Online Access:Verlag, Volltext: https://doi.org/10.1186/s12890-019-0937-0
Get full text
Author Notes:Sebastiano Emanuele Torrisi, Nicolas Kahn, Julia Wälscher, Nilab Sarmand, Markus Polke, Kehler Lars, Monika Eichinger, Claus Peter Heussel, Stefano Palmucci, Francesca Maria Sambataro, Gianluca Sambataro, Domenico Sambataro, Carlo Vancheri, and Michael Kreuter
Description
Summary:Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to these therapies is highly variable, sometimes without meaningful improvement, especially in more fibrosing forms. Pirfenidone and nintedanib have recently demonstrated to reduce functional decline in patients with IPF. However, their antifibrotic mechanism makes these two drugs an interesting approach for treatment of fibrosing ILDs other than IPF.
Item Description:Gesehen am 06.02.2020
Physical Description:Online Resource
ISSN:1471-2466
DOI:10.1186/s12890-019-0937-0

Similar Items